Navigation Links
Endo Announces Compensation for New CFO Alan Levin
Date:5/29/2009

CHADDS FORD, Pa., May 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that the company is granting Alan Levin a sign-on award of 43,500 restricted stock units and an option to purchase 80,000 shares of Endo common stock in connection with his appointment as Endo's executive vice president and chief financial officer. These grants are being made outside of the Endo 2007 stock incentive plan but are subject to the terms and conditions of the plan with a ten-year term and four-year vesting. The option exercise price will be equal to the closing price of Endo's common stock on June 1, 2009, the first day of Mr. Levin's employment with the company.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; VOLTAREN(R) GEL, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; SANCTURA(R) and its XR version for treatment of overactive bladder; VANTAS(R) for the palliative treatment of advanced prostate cancer; and SUPPRELIN(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
2. Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
3. Draeger Announces New Tubes & CMS Handbook - 15th Edition
4. Draeger Announces New Multi-Gas Plus Cartridge
5. Versus Technology, Inc. Announces Spring 09 Release for Added Workflow Automation
6. Versus Technology Announces Second Quarter Results
7. Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline
8. Astellas Announces New Vice President of Marketing
9. Valeant Announces Increase to Securities Repurchase Program
10. Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoints NextRx Subsidiaries
11. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African company ... available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional products. ... in ancient India and Siam. It spread across Asia and Africa quickly, and today ...
(Date:4/24/2017)... HOUSTON, TEXAS (PRWEB) , ... April 24, 2017 ... ... service (SaaS) based healthcare compliance and credentialing solutions, today announced that Kyle Allain ... Allain leads symplr’s Cactus Provider Management sales and operations, including provider, payor and ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Rod Burkett, CEO ... Housing News website. , Rod has been at the forefront of Gardant since it ... As CEO, Rod has overseen the opening of more than 40 new senior living ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
Breaking Medicine Technology: